Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2560-2566

  Guo, Tai L ^a   Chi, Rui P ^a   Hernandez, Denise M ^a   Auttachoat, Wimolnut ^a   Zheng, Jian F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CD4 ANTIGEN; GAMMA INTERFERON; GENISTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; STAT1 PROTEIN; STAT4 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; EXPERIMENTAL MELANOMA; FEMALE; HOST RESISTANCE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TIME; TUMOR IMMUNITY; TUMOR RESISTANCE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENISTEIN; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; STAT1 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 36949034150     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm223     Document Type: Article

References (50)

1. Messina,M.J. et al. (1994) Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr. Cancer, 21, 113-131.
2. King,R.A. et al. (1996) Absorption and excretion of the soy isoflavone genistein in rats. J. Nutr., 126, 176-182.
3. Constantinou,A.I. et al. (1996) Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Res., 16, 3293-3298.
4. Lamartiniere,C.A. et al. (1998) Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc. Soc.-Exp. Biol. Med., 217, 358-364.
5. Peterson,G. (1995) Evaluation of the biochemical targets of genistein in tumor cells. J. Nutr., 125, 784S-789S.
6. Cheng,E.W. et al. (1955) Oestrogenic activity of some naturally occurring isoflavones. Ann. N. Y. Acad. Sci., 61, 637-736.
7. Levy,J.R. et al. (1995) The effect of prenatal exposure to the phytoestrogen genistein on sexual differentiation in rats. Proc. Soc. Exp. Biol. Med., 208, 60-66.
8. Goldwyn,S. et al. (2000) Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metabol. Drug Interact. 17, 261-289.
9. Hsieh,C.Y. et al. (1998) Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res., 58, 3833-3838.
10. Santell,R.C. et al. (2000) Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J. Nutr., 130, 1665-1669.
11. Guo,T.L. et al. (2001) Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. J. Nutr., 131, 3251-3258.
12. Prince,M. et al. (2006) Naturally occurring coumarins inhibit 7,12-dimethylbenz [a]anthracene DNA adduct formation in mouse mammar y gland. Carcinogenesis, 27, 1204-1213.
13. Doerge,D.R. et al. (2000) On-line sample preparation using restricted-access media in the analysis of the soy isoflavones, genistein and daidzein, in rat serum using liquid chromatography electrospray mass spectrometry. Rapid Commun. Mass Spectron., 14, 673-678.
14. Fischer,M.F. et al. (1992) The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-dimethylbenz [a]anthra cene in Sencar mice. Cancer Res., 52, 662-666.
15. Murray,M.J. et al. (1985) Models for the evaluation of tumor resistance following chemical or drug exposure. In Dean,J.H.,Luster,M.I.,Munson,A.E. and Amos,H. (eds.) Immunotoxicology and Immunopharmacology. Raven Press, New York, pp. 113-122.
16. + T cells: A common basis between tumor immunity and auto-immunity. J. Immunol., 163, 5211-5218.
17. Woo,E.Y. et al. (2002) Cutting edge: Regulatory T cells from lung cancer patienti directly inhibit autologous T cell proliferation. J. Immunol., 168, 4272-4276.
18. Fallarino,F. et al. (1999) Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Statl. J. Immunol., 163, 4109-4113.
19. Thierfelder,W.E. et al. (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature, 382, 171-174.
20. Kerkvliet,N.I. et al. (1996) Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Immunol., 157, 2310-2319.
21. Niederkom,J.Y. (1987) T cell subsets involved in the rejection of metastases arising from intraocular melanomas in mice. Invest. Ophthalmol. Vis. Sci., 28, 1397-1403.
22. Dobrzanski,M.J. et al. (2001) Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol., 167, 424-434.
23. Nicol,C.J. et al. (2004) PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenosis. Carcinogenesis 25, 1747-1755.
24. Whiteside,T.L. et al. (1995) The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol., 7, 704-710.
25. Kijkuokool,P. et al. (2006) Genistein enhances N-nitrosomethylurea-induced rat mammary tumorigenesis. Cancer Lett. 242, 53-59.
26. Cohen,L.A. et al. (2000) Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis. Carcinogenesis 21, 929-935.
27. Cabanes,A. et al. (2004) Prepubertal estradiol and genistein exposures upregulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis, 25, 741-748.
28. Fan,S. et al. (2006) BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer, 94, 407-426.
29. Miki,Y. et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
30. Mullan,P.B. et al. (2005) The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene, 24, 5492-5501.
31. Becker,C. et al. (2001) Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med., 7, 1159-1162.
32. Ouchi,T. et al. (2000) Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc. Natl Acad. Sci. USA, 97, 5208-5213.
33. Blankenstein,T. et al. (2003) The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol., 15, 148-154.
34. Buckley,N.E. et al. (2007) BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs. Mol. Cancer Res., 5, 261-270.
35. Simmen,R.C. et al. (2005) Inhibition of NMU-induced mammary tumorigenesis by dietary soy. Cancer Lett., 224, 45-52.
36. + T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol., 12, 1145-1155.
37. + T-cell-dependent immune defense of B16 melanoma. Cancer Res., 61, 8643-8646.
38. Liyanage,U.K. et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol., 169, 2756-2761.
39. Rudge,G. et al. (2007) Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J. Immunol., 178, 4089-4096.
40. Wei,H. et al. (1998) Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis, 19, 1509-1514.
41. Chan,H.Y. et al. (2003) A potential protective mechanism of soya isoflavones against 7,12-dimethylbenz [a]anthracene tumour initiatio n. Br. J. Nutr., 90, 457-465.
42. Irvine,C.H. et al. (1998) Phytoestrogens in soy-based infant foods: Concentrations, daily intake, and possible biological effects. Proc. Soc. Exp. Biol. Med., 217, 247-253.
43. Hodgson,E. (1997) Toxicology testing and risk assessment. In Hodgson,E. and Levi,P.E. (eds.) A Textbook of Modern Toxicology, 2nd edn. Appleton & Lange, Stamford, CT, p. 336.
44. Yellayi,S. et al. (2002) The phytoestrogen genistein induces thymic and immune changes: A human health concern? Proc. Natl Acad. Sci. USA, 99, 7616-7621.
45. Djuric,Z. et al. (2001) Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett., 172, 1-6.
46. Day,J.K. et al. (2001) Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type, but not ER alpha KO, mice. Nutr. Cancer, 39, 226-232.
47. Ueda,M. et al. (2003) Lack of significant effects of genistein on the progression of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. Nutr. Cancer, 47 141-147.
48. Constantinou,A.I. et al. (2001) Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr. Cancer, 41, 75-81.
49. Manjanatha,M.G. et al. (2006) Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz [a]anthracene-induced ma mmary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis, 27, 2555-2564.
50. Gallo,D. et al. (2001) Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res. Treat., 69 153-164.